ClinicalTrials.Veeva

Find clinical trials for Multiple Sclerosis (MS) in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Atlanta, GA, USA:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Drug: Siponimod
Drug: Ofatumumab

Phase 3

Novartis
Novartis

Atlanta, Georgia, United States and 72 other locations

Effects of Stimulation Patterns of Deep Brain Stimulation

with Parkinson's disease (PD), essential tremor (ET), dystonia or multiple sclerosis (MS). These data will guide the desig...

Invitation-only
Multiple Sclerosis
Essential Tremor
Procedure: Symptogenic Stimulation Patterns
Procedure: Therapeutic Stimulation Patterns
Duke University
Duke University

Atlanta, Georgia, United States and 2 other locations

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: Ofatumumab

Phase 3

Novartis
Novartis

Atlanta, Georgia, United States and 122 other locations

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...

Active, not recruiting
Relapse Remitting Multiple Sclerosis
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Atlanta, Georgia, United States and 35 other locations

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Suwanee, Georgia, United States and 225 other locations

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis (VISTA)

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects w...

Enrolling
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: PIPE-307 Dose B

Phase 2

Contineum Therapeutics

Atlanta, Georgia, United States of America and 24 other locations

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response an...

Enrolling
Multiple Sclerosis
Biological: IMS001

Phase 1

ImStem Biotechnology

Atlanta, Georgia, United States and 2 other locations

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.

American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The s...

Active, not recruiting
Multiple Sclerosis, Relapsing
Drug: Ocrelizumab

Phase 4

Genentech
Genentech

Atlanta, Georgia, United States and 30 other locations

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis (CALLIPER)

Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple...

Active, not recruiting
Multiple Sclerosis
Drug: Placebo matching IMU-838
Drug: IMU-838

Phase 2

Immunic Therapeutics

Atlanta, Georgia, United States of America and 72 other locations

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

The ALSpire Study is a clinical trial evaluating the investigational drug BIIB105 in adults living with amyotrophic lateral sclerosis (ALS)....

Active, not recruiting
Amyotrophic Lateral Sclerosis
Drug: Placebo
Drug: BIIB105

Phase 1, Phase 2

Biogen
Biogen

Atlanta, Georgia, United States and 16 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems